Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study.
Stacey N ReinkeShama NazRomanas ChaleckisHector Gallart-AyalaJohan KolmertNazanin Z KermaniAngelica I TiotiuDavid I BroadhurstAnders LundqvistHenric OlssonMarika StrömÅsa M WheelockCristina GómezMagnus EricssonAna R SousaJohn H RileyStewart BatesJames ScholfieldMatthew LozaFrédéric BaribaudPer S BakkeMassimo CarusoPascal ChanezStephen J FowlerThomas GeiserPeter HowarthIldikó HorváthNorbert KrugPaolo MontuschiAnnelie BehndigFlorian SingerJacek MusialDominick E ShawBarbro DahlénSile HuJessica Lasky-SuPeter J SterkKian Fan ChungRatko DjukanovicSven-Erik DahlénIssssswan M AdcockCraig E Wheelocknull nullPublished in: The European respiratory journal (2021)
This is the first large-scale study to delineate disease- and OCS-associated metabolic differences in asthma. The widespread associations with different therapies upon the observed metabotypes demonstrate the necessity to evaluate potential modulating effects on a treatment- and metabolite-specific basis. Altered carnitine metabolism is a potentially actionable therapeutic target that is independent of OCS treatment, highlighting the role of mitochondrial dysfunction in severe asthma.